Scarica l'app Stockscreener
61.93
2.35%
-1.49
Dopo l'orario di chiusura:
61.92
-0.010
-0.02%
Precedente Chiudi:
$63.42
Aprire:
$63.15
Volume 24 ore:
2.03M
Relative Volume:
1.18
Capitalizzazione di mercato:
$13.13B
Reddito:
$2.75B
Utile/perdita netta:
$322.29M
Rapporto P/E:
80.56
EPS:
0.7687
Flusso di cassa netto:
$300.88M
1 W Prestazione:
-6.69%
1M Prestazione:
-11.67%
6M Prestazione:
-20.15%
1 anno Prestazione:
-29.24%
Intervallo 1D:
$61.40
$63.52
Intervallo di 1 settimana:
$61.40
$67.00
Portata 52W:
$61.40
$99.56
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Nome
Biomarin Pharmaceutical Inc
Settore
Industria
Telefono
(415) 506-6700
Indirizzo
105 DIGITAL DRIVE, NOVATO, CA
Confronta BMRN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| BMRN | 61.93 | 13.13B | 2.75B | 322.29M | 300.88M | 0.7687 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-08-20 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2024-05-17 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-05-14 | Iniziato | Evercore ISI | Outperform |
| 2023-11-15 | Iniziato | Wells Fargo | Overweight |
| 2023-10-23 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
| 2023-09-28 | Iniziato | Raymond James | Mkt Perform |
| 2023-09-18 | Iniziato | UBS | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Perform |
| 2023-07-05 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-06-14 | Ripresa | Credit Suisse | Outperform |
| 2023-03-21 | Iniziato | Bernstein | Underperform |
| 2023-02-22 | Downgrade | Oppenheimer | Outperform → Perform |
| 2023-02-21 | Iniziato | Citigroup | Neutral |
| 2023-01-30 | Iniziato | BMO Capital Markets | Market Perform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Hold |
| 2022-10-31 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-06-13 | Ripresa | Wedbush | Neutral |
| 2022-04-25 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2021-10-07 | Ripresa | Jefferies | Buy |
| 2021-09-09 | Aggiornamento | Stifel | Hold → Buy |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-03-04 | Ripresa | Guggenheim | Buy |
| 2021-03-01 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2020-08-20 | Downgrade | Citigroup | Buy → Neutral |
| 2020-08-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2020-08-19 | Downgrade | Evercore ISI | Outperform → In-line |
| 2020-08-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-08-19 | Downgrade | Stifel | Buy → Hold |
| 2020-07-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-06 | Reiterato | Citigroup | Buy |
| 2020-01-28 | Iniziato | BMO Capital Markets | Market Perform |
| 2020-01-27 | Iniziato | BMO Capital Markets | Market Perform |
| 2020-01-24 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-11-27 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-05-23 | Ripresa | Citigroup | Buy |
| 2019-04-09 | Ripresa | Raymond James | Outperform |
| 2019-01-02 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2018-12-14 | Iniziato | Wolfe Research | Outperform |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-08-07 | Reiterato | Stifel | Buy |
| 2018-08-03 | Reiterato | Stifel | Buy |
Mostra tutto
Biomarin Pharmaceutical Inc Borsa (BMRN) Ultime notizie
Layoff Tracker: Gilead Sciences Will Lay Off 104 Employees at California HQ - BioSpace
Sumitomo Mitsui Trust Group Inc. Has $32.06 Million Stock Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BioMarin's VOXZOGO Shows Remarkable Height Gains in 452-Child Achondroplasia Study | BMRN Stock News - StockTitan
Comgest Global Investors S.A.S. Has $713,000 Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Los Angeles Capital Management LLC Acquires New Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BioMarin stock touches 52-week low at $65.23 amid challenges - Investing.com India
BioMarin Pharmaceutical (NASDAQ:BMRN) Hits New 1-Year Low on Insider Selling - MarketBeat
BioMarin Pharmaceutical (NASDAQ:BMRN) Now Covered by Analysts at Wolfe Research - MarketBeat
Biomarin pharmaceutical's CTO sells $350k in stock By Investing.com - Investing.com Nigeria
Biomarin pharmaceutical's CTO sells $350k in stock - Investing.com India
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Not Flying Under The Radar - Simply Wall St
WCM Investment Management LLC Has $1.20 Million Stock Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Implied Volatility Surging for BioMarin Pharmaceutical (BMRN) Stock Options - Zacks Investment Research
abrdn Life Sciences Investors declares $0.50 dividend - MSN
Principal Financial Group Inc. Has $32.20 Million Stock Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
How To Trade (BMRN) - Stock Traders Daily
National Pension Service Grows Stock Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Here’s Why BioMarin Aristotle Large Cap Growth Strategy Divested From Pharmaceutical (BMRN) - Insider Monkey
Robeco Institutional Asset Management B.V. Buys 128,807 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BioMarin to Participate in Three Upcoming Investor Conferences - StockTitan
BioMarin Pharmaceutical (NASDAQ:BMRN) Upgraded at Wedbush - MarketBeat
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term - MSN
BioMarin Pharmaceutical Inc.: Enhancement of Enzyme Replacement Therapy (ERT) Portfolio - Smartkarma
CAMP4 Analyst Highlights Rare Disease Platform Potential - Benzinga
BioMarin's SWOT analysis: rare disease biotech stock faces growth challenges - Investing.com
AlphaCentric Advisors LLC Purchases 16,000 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Ascendis Pharma Faces Challenges With Skytrofa And Yorvipath Pricing: Analysts Weigh In - MSN
Is BioMarin (BMRN) a Solid Growth Stock? 3 Reasons to Think "Yes" - Yahoo Finance
BioMarin (BMRN) Upgraded to Buy: Here's Why - Yahoo Finance UK
BMRN vs. INCY: Which Stock Is the Better Value Option? - Yahoo Finance
Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term - Yahoo Finance
FY2024 Earnings Forecast for BMRN Issued By Leerink Partnrs - MarketBeat
F M Investments LLC Buys New Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Sold by Rice Hall James & Associates LLC - MarketBeat
9 Best Biotech Stocks Of November 2024 - Forbes
Beyond the Balance Sheet: What SWOT Reveals About Biomarin Pharmaceutical Inc (BMRN) - Yahoo Finance UK
Beyond the Balance Sheet: What SWOT Reveals About Biomarin Pharm - GuruFocus.com
Cantor Fitzgerald Issues Positive Estimate for BMRN Earnings - MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q3 2024 Earnings Call Transcript - Insider Monkey
BioMarin Pharmaceutical Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
(BMRN) Proactive Strategies - Stock Traders Daily
Short Interest in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Expands By 5.9% - MarketBeat
William Blair Downgrades BioMarin Pharmaceutical (BMRN) - MSN
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Purchased by abrdn plc - MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Receives $93.67 Average PT from Brokerages - MarketBeat
Earnings call: BioMarin reports robust Q3 growth with VOXZOGO sales surge - Investing.com Canada
BioMarin stock rating downgraded to market perform after Q3 earnings beat - Investing.com Canada
BioMarin stock touches 52-week low at $67.36 amid market shifts - Investing.com India
BioMarin stock rating downgraded to market perform after Q3 earnings beat By Investing.com - Investing.com South Africa
BioMarin stock touches 52-week low at $67.36 amid market shifts By Investing.com - Investing.com South Africa
BioMarin's Pipeline Faces Skepticism As Analyst Questions Future Growth - Benzinga
Biomarin Pharmaceutical Inc Azioni (BMRN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.66%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):